68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.109031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Shangjing Pang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Nuclear Medicine and Molecular Imaging Key La…. Hauptthemen laut MEDLINE: Breast Neoplasms, Quinolines, Radiopharmaceuticals, Heterocyclic Compounds, 1-Ring. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Sichuan Provincial Science and Technology Support Program, National Natural Science Foundation of China, Southwest Medical University.
Abstract (Originalsprache)
Current DOTA-based 68Ga-labeled small-molecule probes targeting HER2 often suffer from limited tumor-specific uptake. To overcome this limitation, we selected Neratinib, a second-generation pan-HER tyrosine kinase inhibitor, and successfully developed a novel PET imaging agent, 68Ga-DOTA-Neratinib. The probe demonstrated high radiochemical yield, excellent in vitro and in vivo stability, and strong binding affinity for the HER2 receptor. Cell uptake assays confirmed specific accumulation in HER2-positive cell lines: uptake in BT-474 and SK-BR-3 cells at 2 h post-incubation was 7.55 ± 1.10 % and 8.18 ± 0.56 %, respectively, significantly higher than that in HER2-negative MCF-7 cells (4.71 ± 0.79 %, P < 0.05). Moreover, micro-PET/CT imaging in HER2-positive tumor-bearing mice showed enhanced tumor uptake and prolonged intratumoral retention of the tracer, though some background blood activity was also observed. These findings suggest that 68Ga-DOTA-Neratinib is a promising small-molecule PET probe for the noninvasive imaging of HER2-positive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China; Nuclear Medicine Institut…
- Nuclear Medicine Oncology Department, 92493 Hospital of PLA, Huludao, China.
Förderung
- Sichuan Provincial Science and Technology Support Program
- National Natural Science Foundation of China
- Southwest Medical University
- National Key Research and Development Program of China
Zitieren
APA
Pang, S., Yan, Y., Ding, H., You, D., Zhang, C., Tan, M., & Chen, Y. (2025). 68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109031
Vancouver
Pang S, Yan Y, Ding H, You D, Zhang C, Tan M, et al. 68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.109031
BibTeX
@article{Pang2025,
author = {Pang, Shangjing and Yan, Yuanzhuo and Ding, Hongyin and You, Die and Zhang, Chunfang and Tan, Min and Chen, Yue},
title = {68Ga-DOTA-Neratinib: A novel small-molecule PET tracer for breast cancer imaging},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.109031}
}
EUVIMED